- Home
- CYTK
as 07-26-2024 4:00pm EST
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 5.6B | IPO Year: | 2004 |
| Target Price: | $78.25 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $25.98 - $110.25 | Next Earning Date: | 08-08-2024 |
| Revenue: | $3,752,000 | Revenue Growth: | -96.17% |
| Revenue Growth (this year): | 94.78% | Revenue Growth (next year): | 474.66% |
Stock Insider Trading Activity of Cytokinetics Incorporated (CYTK)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Blum Robert I | CYTK | President & CEO | Jul 10 '24 | Sell | $54.29 | 11,500 | $624,335.00 | 399,412 | SEC Form 4 |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Jul 9 '24 | Sell | $55.89 | 2,000 | $111,780.00 | 131,004 | SEC Form 4 |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Jul 9 '24 | Sell | $55.91 | 5,300 | $296,323.00 | 133,004 | SEC Form 4 |
| Harrington Robert Arthur | CYTK | Director | Jul 5 '24 | Sell | $54.61 | 253 | $13,816.33 | 15,516 | SEC Form 4 |
| Blum Robert I | CYTK | President & CEO | Jul 1 '24 | Sell | $54.05 | 11,500 | $621,575.00 | 405,145 | SEC Form 4 |
| PARSHALL B LYNNE | CYTK | Director | Jul 1 '24 | Sell | $54.22 | 5,000 | $271,100.00 | 20,600 | SEC Form 4 |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Jun 25 '24 | Sell | $53.71 | 5,300 | $284,663.00 | 133,004 | SEC Form 4 |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Jun 25 '24 | Sell | $53.74 | 2,000 | $107,480.00 | 133,004 | SEC Form 4 |
| PARSHALL B LYNNE | CYTK | Director | Jun 17 '24 | Sell | $52.55 | 5,000 | $262,750.00 | 20,600 | SEC Form 4 |
| Blum Robert I | CYTK | President & CEO | Jun 17 '24 | Sell | $52.60 | 11,551 | $607,582.60 | 427,594 | SEC Form 4 |
| Blum Robert I | CYTK | President & CEO | Jun 17 '24 | Sell | $52.59 | 10,949 | $575,807.91 | 416,645 | SEC Form 4 |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Jun 11 '24 | Sell | $53.05 | 5,422 | $287,637.10 | 137,370 | SEC Form 4 |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Jun 11 '24 | Sell | $53.03 | 2,366 | $125,468.98 | 135,004 | SEC Form 4 |
| Bhanji Muna | CYTK | Director | Jun 10 '24 | Sell | $52.07 | 2,000 | $104,140.00 | 17,631 | SEC Form 4 |
| Blum Robert I | CYTK | President & CEO | Jun 4 '24 | Sell | $48.85 | 22,500 | $1,099,125.00 | 439,145 | SEC Form 4 |
| PARSHALL B LYNNE | CYTK | Director | Jun 3 '24 | Sell | $48.64 | 5,000 | $243,200.00 | 15,600 | SEC Form 4 |
| Harrington Robert Arthur | CYTK | Director | Jun 3 '24 | Sell | $48.64 | 1,580 | $76,851.20 | 15,541 | SEC Form 4 |
| Wong Robert | CYTK | VP, Chief Accounting Officer | Jun 3 '24 | Sell | $48.88 | 13,011 | $635,977.68 | 16,653 | SEC Form 4 |
| Malik Fady Ibraham | CYTK | EVP Research & Development | May 7 '24 | Sell | $65.11 | 14,186 | $923,650.46 | 138,417 | SEC Form 4 |
| Malik Fady Ibraham | CYTK | EVP Research & Development | May 7 '24 | Sell | $65.11 | 1,361 | $88,614.71 | 137,056 | SEC Form 4 |
| HENDERSON JOHN T | CYTK | Director | Apr 25 '24 | Sell | $64.54 | 10,562 | $681,671.48 | 32,070 | SEC Form 4 |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Apr 9 '24 | Sell | $74.31 | 28,605 | $2,125,637.55 | 142,567 | SEC Form 4 |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Apr 9 '24 | Sell | $74.32 | 4,000 | $297,280.00 | 138,567 | SEC Form 4 |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Mar 5 '24 | Sell | $67.53 | 4,000 | $270,120.00 | 138,973 | SEC Form 4 |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Mar 5 '24 | Sell | $67.56 | 28,604 | $1,932,486.24 | 138,973 | SEC Form 4 |
Latest Cytokinetics Incorporated News
CYTK Breaking Stock News: Dive into CYTK Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Cytokinetics to Announce Second Quarter Results on August 8, 2024
Zacks
a day ago
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?
Argus Research
3 days ago
CYTK: Raising target price to $46.00
GuruFocus.com
3 days ago
Insider Sale: EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)
MT Newswires
3 days ago
Cytokinetics Insider Sold Shares Worth $416,246, According to a Recent SEC Filing
Argus Research
10 days ago
CYTK: Raising target price to $45.00
GlobeNewswire
11 days ago
Cytokinetics Announces Seven Upcoming Presentations at the European Society of Cardiology Congress 2024
Investor's Business Daily
16 days ago
Cytokinetics' Wild Ride: CEO Defends Deal That Rattled Wall Street
Compare CYTK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CYTK Cytokinetics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.